ngram’s Post

📣 SPC update ! On 31 January 2024, by a long-awaited decision in the Dana Farber saga, the French Supreme Court has ruled on the definition of a product “protected by a basic patent in force” according to Article 3a) of EC regulation 469/2009. Applying the criteria laid down in the Royalty Pharma case (30 April 2020, C-650/17), the court dismissed the appeal lodged against the Paris court of appeal decision dated 25 May 2022 by considering that the human monoclonal antibody avelumab, which was the subject of the SPC application, although not expressly mentioned in the basic patent, was indeed protected by this patent, since it was specifically identifiable in the light of the teachings of said patent by the person skilled in the art, through known and mastered routine tests, and had not been developed after the filing date of the patent application, following an autonomous inventive step. This case is a rare example of the application of procedural rules allowing the Supreme Court to consult an expert, here a professor of immunology.   🏛 This decision is in line with the rulings of the French Supreme Court on 1 February 2023 in the pembrolizumab and nivolumab cases (see our previous post: https://lnkd.in/eXU-VDeY, in which we referred to the court of appeal ruling in the Dana Faber case which led to the above mentioned decision). For the decision, click below 👇   #wedoIP #intellectualproperty #SPC #patentlitigation #courdecassation #frenchcaselaw

The latest edition of Lexology Getting the Deal Through Pharmaceutical Antitrust is now available and includes a South African analysis by Nick Altini and I, and an EU analysis by my HSF colleagues Kyriakos Fountoukakos Peter Rowland José Muñoz Martínez and Kristien Geeurickx. We hope that you find it a useful guide for local insights into #pharma #competition/ #antitrust/ #regulatory #law   https://lnkd.in/dpCTDMVb  

Physics and human nature have many similarities. You must be aware of Newton’s laws of motion and their applications. However, do you know that these laws apply to human nature as accurately as they apply to physics? What do you think???   Should you need to assess or develop your team members, please do let us know how we (www.assesspro.in) can help you.   #assessments #assessmentcenter #lederashippipeline #managerialeffectiveness #leadershipdevelopment  #assessmentanddevelopmentcenter #linkedin #assesspro #competencyframework #competencyassessment #hiring #highpotentials #promotions #pharma #pharmaceuticals #competency #macleods #sunpharma #cipla #glenmark #mankind #alkem #abbott #zydus #drreddys #glaxo #ipca #pfizer #micro #sanofi #usv #torrent #cadila #lupin #intas  https://lnkd.in/dYHStHkP

In this article by my BLG partners Beverley Moore and Chantal Saunders, read how the Federal Court judicially reviewed a decision relating to Differin®, which contains a different concentration of medicine than specified in the applicable patent. #BLGPublication #IntellectualProperty #Disputes

Continuing with our IPR webinars, here's another interesting one with our Subject matter expert! Join us on 14th March 03-05 pm #ficciipcell #ficciipcourses #patentlaw#patentsearch#ipr

Meet Markus Grammel, Rais Amils and Takanori Abe on September 28 at the 21st Annual Life Science IP Summit in Munich and learn more about the Bolar exemption and its meaning for life science patent practitioners in Europe. Please click below to learn more about the event. #lifescience #ip #Iplaw #bolarexemption #patent #speech #summit #munich

🌟 Join us on June 4, 2024, for The Patent Office Comes to California symposium, presented by the IP Law Section. Experience it in-person at the USPTO’s Silicon Valley Regional Office or via live-stream! (register here >> https://lnkd.in/g_FFQQeJ) Hear from the USPTO and thought leaders from UC Law SF, Morrison Foerster, Google, Netflix, Genentech, Finnegan, Takara Bio, Altos Labs, Nutcracker Therapeutics, and Shiga International. Earn 6 hours of MCLE on top-of-mind patent topics including Section 101, Section 112, practicing before the PTAB, the Unitary Patent Package, practicing before the PTAB, and a special keynote address from the USPTO. 💼 Interested in becoming a sponsor? Let's connect! >> https://lnkd.in/giH3jnGR #PatentOffice #IPSymposium #USPTO #SponsorshipOpportunity 🚀 #MCLE #PTAB #USPTO

Steve Usdin captures the risks of IRA price negotiation exquisitely in this article - perfect analogy of how IRA has shifted the innovation flow, like moving the boulders in a river. Erosion, changes are only seen in time. There is so much hype around IRA reporting in even scholarly journals - thank goodness for BioCentury Inc.

In his latest #IPlaw newsletter, Manatt's Irah Donner explains the Supreme Court's holding that for a #patent to be valid, it must enable a person skilled in the art to make and use the entire class which it claims, i.e., the full scope of the claimed invention. The decision could encourage patent practitioners to draft more detailed specifications with more examples or embodiments, even if this might delay the filing of the patent application. Learn more: